Bladder News and Research

RSS

HHS adds eight substances to 12th Report on Carcinogens

The U.S. Department of Health and Human Services added eight substances to its Report on Carcinogens, a science-based document that identifies chemicals and biological agents that may put people at increased risk for cancer.

13 Jun 2011

AMPYRA ER Tablets improve walking ability in patients with multiple sclerosis

Acorda Therapeutics, Inc. today announced an analysis of pooled clinical trial results showed patients who were responders to AMPYRA (dalfampridine) Extended Release Tablets, 10 mg demonstrated clinically relevant improvements in walking ability as measured by patient self-report on the 12-Item Multiple Sclerosis Walking Scale (MSWS-12), regardless of either their baseline Expanded Disability Status Scale (EDSS) score or baseline walking speed.

7 Jun 2011

Tikcro reports net loss of $30,000 for first quarter 2011

Tikcro Technologies Ltd. today reported results for the first quarter ended March 31, 2011.

7 Jun 2011

Astellas to present positive AGS-1C4D4 phase II data in metastatic pancreatic cancer at ASCO 2011

Astellas Pharma Global Development, Inc., a subsidiary of Astellas Pharma Inc. based in Tokyo, Japan, today announced that it will be presenting data from a phase II study evaluating AGS-1C4D4 in metastatic pancreatic cancer in a poster session at the American Society of Clinical Oncology (ASCO) 2011 Annual Meeting in Chicago.

6 Jun 2011

Sanofi's semuloparin Phase III study data against venous thromboembolism presented at ASCO 2011

Sanofi US announced today results of the pivotal SAVE-ONCO study which demonstrated that, in cancer patients initiating a chemotherapy regimen, investigational semuloparin significantly reduced the risk of the composite of symptomatic-deep vein thromboembolism (DVT), non-fatal pulmonary embolism (PE) or venous thromboembolism (VTE)-related death by 64%, meeting the study primary endpoint.

4 Jun 2011

GW researchers demonstrate Mta1 gene's role in survival of schistosomes

By using mice lacking a crucial gene that controls the process of chromatin remodeling of cytokines including those responsible for inflammation and comparing them to normal wild type mice with the gene, researchers at the George Washington University School of Medicine and Health Sciences have shown that the gene, Mta1, is essential for the parasite Schistosoma haematobium to establish a productive infection and survival in the host.

4 Jun 2011

SBRT is effective for patients with low-to-intermediate-risk prostate cancer: Researchers

In a multicenter clinical trial, UT Southwestern Medical Center researchers have found that higher doses of stereotactic radiation therapy requiring fewer treatments are safe and effective for patients with low-to-intermediate-risk prostate cancer.

4 Jun 2011

New approach for treatment of infections of urinary tract

One in three women will be faced at least once in her life with cystitis, for some the start of a constantly recurring infection. Cystitis is caused by Escherichia coli bacteria which fasten on to the wall of the bladder by means of thread-like structures (pili).

4 Jun 2011

U of Alberta researchers win Canadian Society of Chemistry award

A one-of-a-kind Canadian research group, based in the Faculty of Medicine & Dentistry at the University of Alberta, has now won every award handed out by the Canadian Society of Chemistry for analytical and environmental chemistry.

4 Jun 2011

Patent infringement suit filed against Impax Laboratories in connection with Detrol

Impax Laboratories, Inc. today confirms that Pfizer Inc., Pharmacia & Upjohn Company LLC and Pfizer Health AB have filed suit for patent infringement against Impax in the United States District Court for the District of New Jersey in connection with Detrol (tolterodine tartrate) immediate-release, 1 mg and 2 mg tablets.

4 Jun 2011

Delayed treatment could prove effective in certain medical conditions

In today's fast-paced world, waiting — whether it's at the doctor's office, in line at the grocery store or for an Internet connection — is rarely considered a good thing.

3 Jun 2011

Stereotactic body radiation therapy effective for patients with low-risk prostate cancer

3 Jun 2011

U-M study shows decline in surgery mortality for eight different high-risk operations

Surgery death rates have dropped nationwide over the past decade, according to a University of Michigan Health System study that reveals cancer surgeries have seen the most dramatic improvement in safety.

3 Jun 2011

Wireless near-infrared spectroscopy can effectively detect bladder disease in children

A cell phone-sized, wireless near-infrared device is as reliable as the current "gold standard" invasive tests in determining bladder disease, according to a study by researchers at the University of British Columbia, Vancouver Coastal Health and the Child & Family Research Institute (CFRI).

1 Jun 2011

UK's NICE issues guidance on PTNS treatment for faecal incontinence

Uroplasty, Inc., announced today that the United Kingdom's National Institute for Health and Clinical Excellence issued guidance on percutaneous tibial nerve stimulation for the treatment of faecal incontinence.

31 May 2011

Canadian women more aware of ovarian cancer now, but misconceptions remain

Canadian women know more about ovarian cancer than they did six years ago, but misconceptions remain that could lead to late diagnosis of the country's most fatal gynecologic cancer - a disease that claims the lives of 70% of those diagnosed.

30 May 2011

NovaShunt launches new corporate identity and product branding

NovaShunt AG has launched a new corporate identity and product branding to support its goal of leadership in the area of fluid management within the body. The company will now operate as Sequana Medical AG it prepares for the upcoming launch of the ALFApump System in Europe.

30 May 2011

Lx Therapies, BioCis partner to form Laurantis Pharma

BioCis Pharma Oy and Oy Lx Therapies Ltd. announced today that the companies have combined to create Laurantis Pharma Oy, a clinical-stage specialty pharmaceutical development company.

26 May 2011

Positive interim results from new bladder cancer therapy trial

Clinical trials for a new bladder cancer therapy show promising interim results. Lead researcher Alvaro Morales says that the breakthrough using the drug Urocidin follows thirty years of his research in this important area.

25 May 2011

Nerve stimulation device approved for pain

The Medtronic Inc. has won the CE Mark approval for a peripheral nerve stimulation device for treating chronic back pain. This medical device maker from Minneapolis, Minn. said the implantable device will fit into its neurostimulation business, which operates out of the company's restorative therapies division. That unit was responsible for about $5.42 billion in sales during the nine-month period ended Jan. 28.

From Medtronic 24 May 2011